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Short title: Using sodium to predict acute stroke outcomes  
Abstract  
Objectives: To examine the usefulness of including sodium (Na) levels as a criterion to the 
SOAR stroke score in predicting inpatient and 7-day mortality in stroke. 
Materials & Methods: Data from the Norfolk and Norwich University Hospital Stroke & 
TIA register (2003-2015) were analysed. Univariate and then multivariate models controlling 
for SOAR variables were used to assess the association between admission sodium levels and  
inpatient and 7-day mortality. The prognostic ability of the SOAR and SOAR-Na score for 
mortality outcomes at both time points were then compared using Area Under the Curve 
(AUC) values from Receiver Operating Characteristics.  
Results:  A total of 8,493 cases were included (male=47.4%, mean (s. d.) 77.7 (11.6) years). 
Compared to normonatraemia (135-145mmol/L),  hypernatraemia (>145mmol/L) was 
associated with inpatient mortality and  moderate (125-129mmol/L) and severe hypontraemia 
(<125mmol/L) with 7-day mortality after adjustment for stroke type, Oxfordshire Community 
Stroke Project classification, age, pre-stroke modified Rankin score and sex. The SOAR and 
SOAR-Na scores both performed well in predicting inpatient mortality with AUC values of 
0.794(0.78-0.81) and 0.796(0.78-0.81), respectively. 7-day mortality showed similar results. 
Both scores were less predictive in those with chronic kidney disease (CKD) and more so in 
those with hypoglycaemia.  
Conclusion: The SOAR-Na did not perform considerably better than the SOAR stroke score. 
However, the performance of SOAR-Na in those with CKD and dysglycaemias requires 
further investigation. 
Key Words: Acute stroke, dysnatraemia, mortality, prognosis  
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Introduction   
 
Acute stroke mortality remains high (1) with most deaths occurring early as inpatient deaths 
(2). Numerous prognostic scores previously developed are limited by various factors 
including complexity (3) and prediction limited to either ischaemic or haemorrhagic stroke 
(4-7). We developed the SOAR stroke score as a simple 8 point (score values 0-7) prognostic 
score that predicts inpatient and 7-day mortality for both stroke subtypes. It takes into 
account four readily available variables: Stroke subtype, Oxfordshire Community Stroke 
Project (OCSP) Classification, Age and pre-stroke modified Rankin score (pre-stroke mRs; 
indicative of pre-stroke disability). Haemorrhagic, and total anterior circulation stroke 
(TACS), older age and extensive  pre-stroke disability are weighted with a higher score and 
are  associated with greater risk for  early mortality (8). Supplementary Table 1 demonstrates 
how values for these variables are scored (along with the proposed scores for sodium 
categories). Though not currently in clinical use, external validation of the SOAR stroke 
score has shown that it is accurate in predicting mortality (9).  
Dysnatraemia, either hypo- or hypernatraemia, is the commonest electrolyte abnormality in 
hospitalised patients (10). Indeed, both hypo- and hypernatraemia have been shown to 
increase inpatient mortality in various settings including intensive care units and emergency 
departments (10-12). Recently, studies have established that hyponatraemia increases both 
short and long term mortality in stroke patients (13-15). We hypothesise that the addition of 
sodium levels would improve the performance of SOAR stroke score.  
The current study aimed to examine if the addition of sodium levels (forming the SOAR-Na 
score) would considerably better the prognostic ability of the SOAR stroke score.  Also of 
interest was to explore the performance of the SOAR-Na score in comparison to the SOAR 
stroke score in patient populations characterised by conditions that may particularly influence 
sodium handling and levels -  those with or without chronic kidney disease (CKD) and those 
with or without hyperglycaemia, respectively.   
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Materials & Methods  
 
The participants were drawn from the Norfolk and Norwich University Hospital Stroke & 
TIA register (NNUSTR) which has a catchment population of ~750,000.  This register has 
recorded consecutive stroke patients since its inception in 1996 and blood results were 
available from electronic records from 2003. For this study purpose we included patients 
consecutively admitted between January 2003 and May 2015.  The Newcastle and Tyneside 
National Health Service Research Ethics Committee granted ethical approval (12/NE/0170).     
The variables included in this study were sex, plasma sodium levels on admission (same day 
or closest to admission), status at discharge (dead or alive), dates of admission and discharge. 
In addition to this were all variables needed to calculate the SOAR stroke score: age, pre-
stroke mRs, stroke subtype and OCSP classification. The outcomes of interest were inpatient 
and 7-day mortality.  Inpatient mortality refers to patients who die before discharge from 
hospital, while 7-day mortality refers to death within 7 days regardless of status at discharge.  
Sodium levels on admission were split into five categories based on standard cut off points 
used in clinical practice. These were severe hyponatraemia (<125mmol/L), moderate 
hyponatraemia (125-129mmol/L), mild hyponatraemia (130-134mmol/L), normonatraemia 
(135-145mmol/L) and hypernatraemia (>145mmol/L). Cases were excluded for various 
reasons, these are summarised in Figure 1.  
Statistical Analysis 
Analysis was performed using SPSS V.23.0 (Chicago, Illonois, US). Univariate and then 
multivariate logistic regression models were constructed for both inpatient and 7-day 
mortality outcomes. The results of the multivariate model that adjusted for SOAR variables 
were used to assign score values for sodium categories. Then, a separate logistic regression 
model was constructed to check the value of points assigned to sodium categories. This 
analysis adjusted for a calculated SOAR stroke score as opposed to actual values of 
individual variables. Based on the results of these models, both severe hyponatraemia and 
hypernatraemia were assigned one point each and added to the SOAR stroke score, forming 
the SOAR-Na stroke score (Supplementary Table 1). 
Due to relatively small numbers of patients who scored very high scores, those with scores 5 
and 6 were combined for SOAR and those who were scoring 5, 6 and 7 were combined for 
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the SOAR-Na score.  The diagnostic ability of the SOAR and SOAR-Na score for both 
inpatient and 7-day mortality was determined by sensitivity, specificity, negative predictive 
value (NPV) and positive predictive value (PPV) for each increment of the score point. Then 
the discriminating ability of SOAR and SOAR-Na was compared using receiver operating 
characteristic (ROC) curves. An analysis was also run stratifying those whose sodium level 
were taken at the same day of admission and those whose level was measured afterwards. 
Sub-analyses were conducted using STATA (Version 14.0). This analysis involved 
stratifying each of the ROC curves by diagnosis of chronic kidney disease or by glucose 
levels: Glucose categories were hypoglycaemia (<4.0mmol/L), normoglycaemia (4.0-
7.8mmol/L), borderline hyperglycaemia (7.9-11.0mmol/L) and hyperglycaemia 
(>11.0mmol/L).  Some had missing data for glucose levels at admission, thus for glucose 
analysis the sample consisted of 6,550 patients. 
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Results  
 
The NNUSTR had a total of 11,886 entries between January 2003 and May 2015. Of them, 
3393 records were excluded from the current study (see Figure 1 for exclusions).The included 
cases had similar characteristics compared to the whole sample (Supplementary Table 2). A 
total of 8,493 patients with acute stroke were  included in the study. The sample mean age 
was 77.7 years (SD ±11.6 years), 47.4% were male. Approximately 19.5% of cases died as 
inpatients and 9.5% died within 7 days of admission.  Table 1 shows the sample 
characteristics. 88.4% of the sample had an ischaemic stroke and the most common OCSP 
classification was partial anterior circulation stroke (35.7%). 63.7% of the patients had no 
pre-stroke disability (pre-stroke mRs=0) and the majority of cases (84.3%) had normal 
sodium levels on admission. The baseline point prevalence of hypernatraemia was 1.8%. The 
prevalences for mild, moderate and severe hyponatraemia were 10.6%, 2.6% and 0.7%, 
respectively.  
Univariate analysis showed that all levels of dysnatraemia had increased odds of both 
inpatient and 7-day mortality. Hypernatraemia appeared to have the largest impact on 
inpatient mortality, OR 3.04 (95% CI: 2.18-4.24) while severe hyponatraemia had the largest 
impact for 7-day mortality OR 3.00 (1.61-5.60).  Multivariate analysis controlling for SOAR 
stroke score variables showed that those with hypernatraemia were more likely to die as an 
inpatient in comparison to those with normal sodium levels (OR 2.56 (1.71-3.84)). In 
contrast, moderate and severe hyponatraemia showed statistical significance for predicting 7-
day mortality, the latter appearing to have the highest risk: ORs 2.00 (1.33-3.01) and 3.13 
(1.56-6.29), respectively (Table 2). Analysis utilising the SOAR stroke score as a single 
categorical variable revealed similar results (Supplementary Table 3).   
When predicting inpatient mortality the SOAR stroke and SOAR-Na scores achieved AUC 
values of 0.794 (95% CI: 0.78-0.81) and 0.796 (95% CI: 0.78-0.81) respectively. Similar 
values were observed for 7-day mortality: respective AUC values were 0.784 (0.77-0.80) and 
0.785 (0.77-0.80).   A statistically significant difference between the two scores was observed 
when predicting in-patient mortality (p value = 0.04), though the absolute improvement was 
minimal. Sodium levels were measured on the same day for the majority of the sample 
(84.7%).  Repeating the analysis stratifying those whose sodium level was taken at the same 
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day of admission and those whose level was measured afterwards showed little difference in 
the predictive ability of the either the SOAR or SOAR-Na score (data not shown).   
The sensitivities, specificities, PPVs and NPVs for each increment of score point for the 
SOAR stroke and SOAR-Na scores are shown for both mortality outcomes in Table 3. Both 
scores performed better in those without CKD compared with those with CKD for both 
mortality time points. In relation to glucose categories, both scores’ predictive ability for 
inpatient and 7-day mortality are statistically significantly higher in patients with 
hypoglycaemia. Both scores also performed better in those with normoglycaemia when 
predicting 7-day mortality (though to a lesser degree) (Table 4).  
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Discussion  
 
Our findings support previously observed associations between dysnatraemia and early 
mortality in stroke (13-15).  A U-shaped relationship is present with severe and moderate 
hyponatraemia and hypernatraemia showing statistical significance once other variables 
relevant to the SOAR stroke score were adjusted for.  Increased odds of mortality displayed 
in those with hyponatraemia may be attributed to osmotic changes causing cerebral oedema 
and increased intracranial pressure leading to a subsequent increase in cell dysfunction and 
death (13).  Excess mortality observed in those with hypernatraemia may be due to 
neurological impairment (12), but is more likely to be a marker of dehydration and advanced 
frailty (15). Hypernatraemia has also been associated with early neurological worsening (16).  
In comparison to preceding literature, the models utilised to predict mortality outcomes had a 
much smaller degree of adjustment (13-15).The aim of the models used within this paper was 
to establish if sodium levels perform independently of the variables used within the SOAR 
stroke score.  Considerably fewer variables were therefore controlled for. This is important to 
note in respect to hypernatraemia’s association with mortality. Soiza et al’s (15) sample is 
comparable to the one in this study (theirs is taken from the same register but from an earlier 
time point). Although Soiza et al. (15) also showed this association, this was lost when serum 
urea, another measure of dehydration, was controlled for along with other haematological and 
biochemistry variables.  
The addition of sodium to the SOAR stroke score does not appear to make a noteworthy 
impact on the score’s predictive ability. While there is a statistically significant difference 
when predicting inpatient mortality, the minor difference in absolute terms means this is 
unlikely to be a useful tool over SOAR. Similarly, the SOAR-Na score was not superior to 
the SOAR stroke score with regard to 7-day mortality prediction.  The minor increase in 
performance observed may be partly attributed to the fact that higher scores were combined 
in both indices (due to their small numbers), perhaps reducing the discriminative ability of 
the SOAR-Na score. An alternative possible explanation is the presence of a mechanistic link 
between the SOAR stroke score and dysnatraemias. Dysnatraemias could possibly mediate 
the poor outcome in patients with characteristics fulfilling a high SOAR stroke score (e.g. 
older age, higher pre-stroke mRs, more severe stroke).  
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Myint et al. (8) have shown that the SOAR stroke score accurately predicts length of stay, 
this has been validated by the same group (17).While not examined within this study, the 
addition of sodium may be more useful in predicting length of stay as opposed to early 
mortality outcomes. Hyponatraemia has not only been independently associated with an 
increased length of stay within an unselected population (18-19) but also increased use of 
hospital resources and cost (18-19).     
The SOAR-Na score appears to perform poorly in those with CKD (though still marginally 
better than the SOAR stroke score). Within this sub-group, renal function is the main 
determinant of outcome (20) and compromised water homeostasis means that dysnatraemias 
are more likely (20-22). It is worth noting that the sample size was small when we confined 
analysis to those with history of CKD. Additional research with a larger sample would be 
required to confirm or refute the current study findings. 
Both the SOAR and SOAR-Na score’s predictive ability was considerably increased in those 
with hypoglycaemia for both mortality outcomes. An unexpected finding was the SOAR 
stroke score actually performed slightly better. This finding, however, could be influenced by 
the small number of cases (N=56) within this category. While the overall sample size is 
reasonable (>6,500 cases) individual categories held small numbers of cases possibly 
contributing to non-significant results. As glucose concentration rises, sodium concentration 
falls due to water shifts from the intracellular to extracellular compartment. Examining how 
this could impact the performance of the SOAR-Na score in a larger sample would be of 
interest. 
In conclusion, this study further supports that sodium is an independent predictor of mortality 
after stroke. The addition of sodium levels as a criterion to the SOAR stroke score, however, 
does not make a substantial increase in the score’s predictive ability with regard to 7- day and 
inpatient mortality outcomes. Nonetheless, the performance of the SOAR-Na score may still 
be of interest in particular groups, namely those with dysglycaemia and CKD and other 
patient related outcomes. 
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Table 1:  Sample characteristics by total sample, those who died as in-patient and within 7 days of admission 
  Total sample n  Inpatient Death  7-Day Mortality  
   n=1652  n=808  
Age category ≤65 1267 (14.9) 84 (5.1) 60 (7.4) 
66-85 4937( 58.1) 864 (52.3) 446 (55.2) 
 ≥86 2289 (27.0) 704 (42.6) 302 (37.4) 
     
Sex Male 4025 (47.4) 672 (40.7) 322 (39.9) 
Female 4468 (52.6) 980 (59.3) 486 (60.1) 
     
Stroke Type Ischaemic 7508 (88.4) 1306 (79.1) 581 (71.9) 
 Haemorrhagic 985 (11.6) 346 (20.9) 227 (28.1) 
     
OCSP Classification TACS 1847 (21.7) 921 (55.8) 498 (616.6) 
PACS 3033 (35.7) 355 (21.5) 119 (14.7) 
LACS 2087 (24.6) 114 (6.9) 41 (2.1) 
POCS 1526 (18.0) 262 (15.9) 150 (18.6) 
     
Pre-stroke modified 
Rankin score 
0 5406 (63.7) 784 (47.5) 424 (52.5) 
1 1021 (12.0) 215 (13.0) 94 (11.6) 
2 716 (8.4) 191 (11.6) 86 (10.6) 
3 805 (9.5) 232 (14.0) 101 (12.5) 
4 388 (4.6) 153 (9.3) 72 (8.9) 
5 157 (1.8) 77 (4.7) 31 (3.8) 
     
Sodium level (mmol/L) Severe hyponatraemia 
(<125) 
 
58 (0.7) 18 (1.1) 13 (1.6) 
 Moderate hyponatraemia 
(125-129) 
223 (2.6) 54 (3.3) 36 (4.5) 
 Mild hyponatraemia  900 (10.6) 219 (13.3) 106 (13.1) 
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(130-134) 
 Normonatraemia  
(135-145) 
7163 (84.3) 1301 (78.8) 628 (77.7) 
 Hypernatraemia  
(>145) 
149 (1.8) 60 (3.6) 25 (3.1) 
Abbreviations: OCSP - Oxfordshire Community Stroke Project Classification,  TACS – total anterior circulation stroke, PACS- partial anterior 
circulation stroke, LACS- lacunar stroke, POCS – posterior circulation stroke.  Data presented are number (%). 
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Table 2:  Odds Ratios and corresponding 95% Confidence Intervals (95%CI) for inpatient and 7-day mortality (Multiple regression model)* 
  Inpatient mortality 7-day mortality 
  OR 95% CI P OR 95% CI P 
Sodium level** 
(mmol/L) 
Normonatraemia (135-145) 1.00   1.00   
Mild hyponatraemia (130-
134) 
1.17 [0.96-1.41] 0.11 1.16 [0.91-1.47] 0.24 
Moderate hyponatraemia    
(125-129) 
1.29 [0.90-1.84] 0.17 2.00 [1.33-3.01] =0.001 
Severe hyponatraemia (<125) 1.84 [0.97-3.49] 0.06 3.13 [1.56-6.29] =0.001 
Hypernatraemia (>145) 2.56 [1.71-3.84] <0.001 1.59 [0.97-2.59] 0.06 
   
Age category 
≤65 1.00   1.00   
66-85 2.46 [1.92-3.15] <0.001 1.59 [1.19-2.13] <0.001 
≥86 4.42 [3.41-5.74] <0.001 2.06 [1.51-2.82] <0.001 
   
OCSP Classification 
LACS 1.00   1.00   
TACS 16.02 
[12.90-
19.91] 
<0.001 
15.24 
[10.97-
21.18] 
<0.001 
PACS 2.15 [1.72-2.69] <0.001 1.84 [1.28-2.65] =0.001 
POCS 3.48 [2.74-4.43] <0.001 4.52 [3.16-6.47] <0.001 
   
Pre-stroke modified 
Rankin score 
0 1.00   1.00   
 1 1.56 [1.29-1.88] <0.001 1.18 [0.92-1.52] 0.20 
 2 2.01 [1.63-2.49] <0.001 1.51 [1.15-1.98] <0.001 
 3 2.09 [1.71-2.55] <0.001 1.50 [1.16-1.94] <0.001 
 4 3.03 [2.35-3.92] <0.001 2.16 [1.59-2.95] <0.001 
 5 3.98 [2.72-5.82] <0.001 1.90 [1.21-2.99] 0.01 
   
Stroke type Haemorrhagic 1.00   1.00   
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 Infarct 0.41 [0.34-0.48] <0.001 0.33 [0.28-0.40] <0.001 
 
Abbreviations: OCSP - Oxfordshire Community Stroke Project Classification,  TACS – total anterior circulation stroke, PACS- partial anterior 
circulation stroke, LACS- lacunar stroke, POCS – posterior circulation stroke. 
*All variables were included in the model simultaneously 
**Additional adjustment of sodium concentration respective to glucose concentration did not affect mortality outcomes.   
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Table 3: The sensitivity, specificity, positive predictive value, negative predictive value and corresponding 95% confidence intervals of the 
SOAR stroke and SOAR-Na score for inpatient and 7 day mortality    
Inpatient mortality 
 No. 
Cum 
% 
Total 
with 
score 
Sensitivity 95% CI Specificity 95% CI PPV 95% CI NPV 95% CI 
SOAR  stroke score 
0 20 1.2 676         
≥1 1632 11.2 7817 98.79 [98.14-99.26] 9.59 [8.90-10.31] 20.88 
[19.98-
21.80] 
97.04 
[95.47-
98.18] 
≥2 1467 28.4 5021 88.80 [87.18-90.28] 48.05 
[46.86-
49.24] 
29.22 
[27.96-
30.50] 
94.67 
[93.87-
95.40] 
≥3 1183 57.6 2813 71.61 [69.37-73.77] 76.17 
[75.15-
77.18] 
42.05 
[40.22-
43.90] 
91.74 
[91.00-
92.45] 
≥4 700 85.7 1177 42.37 [39.98-44.80] 93.03 
[92.40-
93.62] 
59.47 
[56.61-
62.29] 
86.99 
[86.19-
87.75] 
≥5 235 99.9 335 14.23 [12.58-16.00] 98.54 
[98.22-
98.81] 
70.15 
[64.94-
75.00] 
82.63 
[81.79-
83.45] 
SOAR-Na score 
0 17 1.0 661         
≥1 1635 10.7 7832 98.97 [98.36-99.40] 9.41 [8.73-10.13] 20.88 
[19.98 
21.79] 
97.43 
[95.91-
98.49] 
≥2 1474 27.6 5062 89.23 [87.63-90.68] 47.55 
[46.36-
48.74] 
29.12 
[27.87 
30.39] 
94.81 
[94.02-
95.53] 
≥3 1194 56.1 2864 72.28 [70.05-74.42] 75.59 
[74.55-
76.60] 
41.69 
[39.88 
43.52] 
91.86 
[91.12- 
92.56] 
≥4 724 84.5 1231 43.48 [41.42-46.26] 92.59 
[91.94-
93.20] 
58.81 
[56.01 
61.58] 
87.22 
[86.43-
87.98] 
≥5 255 99.9 364 15.44 [13.73-17.27] 98.41 
[98.08-
98.69] 
70.05 
[65.06 
74.72] 
82.81 
[81.98- 
83.63] 
7-day mortality 
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 No. 
Cum 
% 
Total 
with 
score 
Sensitivity 95% CI Specificity 95% CI PPV 95% CI NPV 95% CI 
SOAR stroke score 
0 11 1.4 676         
≥1 797 8.9 7817 98.64 [97.58-99.32] 8.65 [8.03-9.30] 10.20 [9.53-0.89] 98.37 
[97.11-
99.18] 
≥2 736 24.6 5021 91.09 [88.91-92.96] 44.24 
[43.13-
45.36] 
14.66 
[13.69-
15.67] 
97.93 
[97.40-
98.37] 
≥3 609 55.2 2813 75.37 [72.25-78.31] 71.32 
[70.30-
72.33] 
21.65 
[20.14-
23.22] 
96.50 
[95.99-
96.96] 
≥4 362 83.7 1177 44.80 [41.34-48.31] 89.39 
[88.69-
90.07] 
30.76 
[28.13-
33.48] 
93.90 
[93.33-
94.44] 
≥5 132 100 335 16.34 [13.85-19.07] 97.36 
[96.97-
97.71] 
39.40 
[34.14-
44.86] 
91.71 
[91.09-
92.30] 
SOAR-Na score 
0 9 1.1 661         
≥1 799 8.6 7832 98.89 [97.90-99.49] 8.48 [7.87-9.13] 10.20 [9.54-10.89] 98.64 
[97.43-
99.38] 
≥2 738 23.9 5062 91.34 [89.18-93.18] 43.73 
[42.62-
44.85] 
14.58 
[13.62-
15.58] 
97.96 
[97.43-
98.41] 
≥3 614 53.6 2864 75.99 [72.89-78.90] 70.72 
[69.69-
71.74] 
21.44 
[19.95-
22.99] 
96.55 
[96.04-
97.01] 
≥4 374 82.4 1231 46.29 [42.81-49.80] 88.85 
[88.12-
89.54] 
30.38 
[27.82-
33.04] 
94.02 
[93.45-
94.56] 
≥5 141 99.9 364 17.45 [14.89-20.25] 97.10 
[96.70-
97.46] 
38.74 
[33.70-
43.95] 
91.79 
[91.18-
92.38] 
 
Abbreviations: No. = number of deaths, Cum% = cumulative percentage  of those who died, PPV = positive predictive value, NPV = negative 
predictive value.  
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Table 4:  Comparison of predictive ability of SOAR stroke and SOAR-Na scores for 7-day and inpatient mortality in all patients and stratified 
by presence of chronic kidney disease and by glucose categories 
 N SOAR stroke score SOAR-Na score 
  AUC value 95% CI AUC value 95% CI  
Inpatient mortality 
All cases 8493 0.794 [0.78-0.81] 0.796 [0.78-0.81] 
      
CKD Diagnosis      
No 8229 0.798 [0.79-0.81] 0.800 [0.79-0.81] 
Yes 264 0.704 [0.63-0.77] 0.707 [0.64-0.78] 
      
Glucose category      
Normoglycaemia 4851 0.783 [0.77-0.80] 0.786 [0.77-0.80] 
Hypoglycaemia 56 0.899 [0.80-1.00] 0.889 [0.79-0.99] 
Borderline 
hyperglycaemia 
1083 0.780 [0.75-0.81] 0.778 [0.75-0.81] 
Hyperglycaemia  560 0.778 [0.73-0.82] 0.780 [0.74-0.82] 
      
7-day mortality 
All cases 8493 0.784 [0.77-0.80] 0.785  [0.77-0.80] 
      
CKD Diagnosis      
No 8229 0.787 [0.77-0.80] 0.788 [0.77-0.80] 
Yes 264 0.702 [0.61-0.79] 0.702 [0.62-0.79] 
      
Glucose category      
Normoglycaemia 4851 0.787 [0.76-0.81] 0.790 [0.77-0.81] 
Hypoglycaemia 56 0.832 [0.67-1.00] 0.825 [0.66-0.99] 
Borderline 
hyperglycaemia 
1083 0.732 [0.69-0.77] 0.731 [0.69-0.77] 
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Hyperglycaemia  560 0.748 [0.69-0.80] 0.749 [0.70-0.80] 
Abbreviations: CKD – chronic kidney disease. 
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Supplementary Table 1: Scoring System for SOAR-Na index 
Patient Variables Score Variable Score 
Age categories ≤60 0 Pre-stroke mRS 0 0 
61-65 0 1 0 
66-70 1 2 0 
71-75 1 3 1 
76-80 1 4 1 
81-85 1 5 2 
86-90 2   
91> 2   
      
OCSP classification TACS 2 Sodium level Normonatraemia 0 
 PACS 0  Mild hyponatraemia 0 
 LACS 0  Moderate 
hyponatraemia 
0 
 POCS 1  Severe hyponatraemia 1 
    Hypernatraemia 1 
Stroke type Ischaemic 0    
 Haemorrhagic 1 Gender Male 0 
    Female 0 
Abbreviations: OCSP - Oxfordshire Community Stroke Project Classification,  TACS – total anterior circulation stroke, PACS- partial anterior 
circulation stroke, LACS- lacunar stroke, POCS – posterior circulation stroke. 
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Supplementary Table 2: Comparison of sample characteristics and whole NNSTR characteristics 
 NNSTR 2015 Dataset *
 
Sample 
Number (n) 10688 8493 
Age  77.7 (11.99) 77.7 (11.76) 
Female 5591 (52.3) 4468 (52.6) 
Male 5097 (47.7) 4025 (47.4) 
Ischaemic stroke type 9248 (86.5) 7508 (88.4) 
Haemorrhagic stroke type 1440 (13.5) 985 (11.6) 
Transient Ischaemic Attack 309 (2.9) 237 (2.9) 
Dementia 490 (4.6) 348 (4.1) 
Previous Myocardial Infarction 519 (4.9) 409 (4.8) 
Peripheral Vascular Disease 274 (2.6) 220 (2.6) 
Chronic Kidney Disease 346 (3.2) 264 (3.1) 
Congestive Heart Failure 906 (8.5) 733 (8.6) 
Diabetes Mellitus 1056 (9.9) 846 (10.0) 
Atrial Fibrillation 1645 (15.4) 1300.3) 
*To be comparable to study sample, those with SAH, undetermined type of stroke (i.e. not ischaemic, haemorrhagic or SAH)  and second entries 
into the dataset are excluded. 
 Brackets indicate standard deviation for continuous data and percentage for categorical data.  
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Supplementary Table 3:  Odds Ratios and corresponding 95%Confidence Intervals (95%CI) for inpatient and 7-day mortality (model using 
SOAR score) 
  Inpatient death 7 Day Mortality 
  OR 95% CI  P OR 95% CI  P 
Sodium level Normonatraemia  1   1   
Mild hyponatraemia 1.15 [0.95-1.39] 0.15 1.09 [0.86-1.37] 
 
0.50 
Moderate hyponatraemia 1.28 [0.90-1.82] 0.17 1.85 [1.25-2.75] <0.001 
Severe hyponatraemia 1.7 [0.91-3.18] 0.10 2.60 [1.33-5.10] 0.01 
Hypernatraemia  2.45 [1.66-3.63] <0.001 1.44 [0.90-2.32] 0.13 
 
SOAR stroke score 0 1      
1 2.07 [1.29-3.32] <0.001 1.34 [0.70-2.56] 0.38 
2 4.80 [3.02-7.63] <0.001 3.58 [1.92-6.67] <0.001 
3 13.59 [8.60-21.48] <0.001 10.49 [5.69-19.33] <0.001 
4 40.05 [25.14-
63.81] 
<0.001 22.21 [12.01-
41.10] 
<0.001 
5 77.15 [46.01-129-
36] 
<0.001 40.38 [21.20-
76.92] 
<0.001 
6 66.14 [33.03-
132.43] 
<0.001 29.32 [13.28-
64.72] 
<0.001 
 
 
Page 23 of 24
Acta Neurologica Scandinavica - PROOF
Acta Neurologica Scandinavica - PROOF
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
PROOF
Figure 1.  Flow diagram for selection of cases 
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